Overview
Cortagen is a synthetic tetrapeptide (Ala-Glu-Asp-Pro) developed within Vladimir Khavinson's peptide bioregulator research programme at the St. Petersburg Institute of Bioregulation and Gerontology. It is classified as a "brain cortex bioregulator" — one of a family of very short peptides Khavinson's group designed to mimic naturally occurring tissue-specific regulatory peptides, on the theory that each organ produces its own short peptide signals that decline with age. Cortagen's proposed target tissue is the cerebral cortex, and it is studied within this programme for cognitive and neuroprotective research applications.
It is important to state plainly what the evidence base for Cortagen actually looks like: almost all published research originates from Khavinson's own laboratories or closely affiliated Russian institutions, published largely in Russian-language journals or their English-language sister publications (e.g.
Bulletin of Experimental Biology and Medicine,
Advances in Gerontology). There is no independent Western replication, no registered Western clinical trial, and no regulatory approval for Cortagen as a medicine in the EU, UK, or Ireland. Readers should treat the findings below as a specific, narrow research literature — not as consensus science — and weigh that context heavily.
Within that literature, Cortagen is studied mainly in aged rodent models for effects on cortical neuron function, cognitive restoration markers following induced brain injury, and general support of cortical tissue during age-related decline. This guide is for educational and research purposes only. Not medical advice.
Clinical & Research Status
| Evidence Type |
Status |
| Human RCT (Western) |
✗ |
| Human RCT (Russian, small-scale) |
✔ (limited) |
| Animal Studies |
✔ |
| In Vitro |
✔ |
| Regulatory Approval (Ireland/EU) |
✗ |
Mechanism of Action
Cortagen's proposed mechanism is not receptor-based in the way conventional pharmaceuticals are described. Khavinson's peptide bioregulator theory proposes that very short peptides (2-4 amino acids) can interact directly with gene promoter regions or chromatin, modulating transcription of genes relevant to the tissue the peptide is derived from — in this case, cortical brain tissue. This is a substantially different and far less mechanistically established framework than classical receptor pharmacology.
Preclinical papers from the Khavinson group report that Cortagen has been observed to support normalisation of protein synthesis markers in cortical neurons of aged and injured animal models, and to has been observed to support recovery of cognitive task performance following induced cortical injury. Proposed downstream effects include modulation of neurotrophic factor expression and support of neuronal survival pathways in cortical tissue under stress. These mechanisms are reported almost exclusively by the originating research group and have not been independently confirmed through Western peer-reviewed replication.
Research Areas & Reported Effects
Cognitive Restoration After Cortical Injury
A portion of Cortagen-specific research relates to recovery of cognitive task performance in rodent models following induced cortical injury or ischaemic events. Reported findings describe has been observed to support in learning and memory task scores in treated animals relative to untreated injury controls, proposed to relate to support of surviving cortical neuron function during the recovery window.
Age-Related Cortical Decline Models
Several Khavinson-affiliated papers report on Cortagen administration in aged rodent models (including SAMP8 accelerated-ageing strains used in Russian gerontology research), describing has been observed to support in cortical function markers and task performance relative to untreated aged controls.
Neuroprotection and Cortical Tissue Support
Preclinical literature describes Cortagen's proposed role in supporting cortical neuron resilience under oxidative and metabolic stress, with reported reductions in markers of cortical tissue damage in animal injury models. These are presented as evidence for a general cortex-directed neuroprotective profile within the originating research programme.
Research Data Summary
| Study / Model |
Reported Effect |
| Rodent Cortical Injury Model (Khavinson et al.) |
Reported improvement in cognitive task recovery following induced cortical injury. |
| SAMP8 Accelerated-Ageing Mouse Model |
Reported improvement in cortical function and memory task performance relative to untreated aged controls. |
| Aged Rat Cortical Tissue Model |
Reported normalisation of protein synthesis markers in cortical neurons. |
| In Vitro Cortical Neuron Culture |
Reported support of neuron survival markers under induced metabolic stress. |
Stack Combinations Studied
- Cortagen + Pinealon → Research rationale: Explored in Russian gerontology literature as a combined "CNS-tissue" bioregulator pairing — cortical and pineal bioregulators studied together for broader neuroprotective and cognitive research aims.
- Cortagen + Cardiogen → Research rationale: Both are Khavinson-programme tetrapeptides studied in adjacent organ-support research tracks; considered together in some Russian literature on multi-organ ageing support, though the combination itself is not a distinct study focus.
⚠️ Stack combinations listed for research reference only. Not safety or efficacy guidance.
Research Protocol Reference
experimental research protocols only — not dosing recommendations.
| Protocol |
Dose (experimental model only) |
Duration (experimental model only) |
Frequency (experimental model only) |
Research Context |
| Rodent Research Protocol |
Model-dependent, mcg/kg range reported in Russian literature |
10-20 days |
Once daily |
Cortical injury recovery and cognitive task studies in aged and injured rodents. |
| Russian Small-Scale Human Study Protocol |
Reported as intranasal administration in limited Russian trials |
10-day course |
As per study protocol |
Reported in small Russian clinical research on post-injury cognitive markers; not independently replicated. |
Observed Side Effects in Research
- No significant adverse events reported in the available Khavinson-affiliated literature
- Independent Western safety data is not available
- Long-term human safety data does not exist outside limited Russian research settings
Because independent Western toxicology and safety studies have not been conducted, the absence of reported side effects in the existing literature should not be read as an established safety profile.
Compound Data
- CAS Number
- Not consistently assigned in Western chemical registries
- Molecular Formula
- C17H26N4O9 (Ala-Glu-Asp-Pro tetrapeptide)
- Molecular Weight
- Approximately 426.4 g/mol
- Half-Life
- Not established in independently published pharmacokinetic literature
- Synonyms
- Ala-Glu-Asp-Pro, AEDP peptide, cortex bioregulator peptide
- Research Classification
- Khavinson-class short peptide bioregulator, tissue-specific (cerebral cortex/CNS) research peptide
Scientific References
The references below are drawn from Vladimir Khavinson's peptide bioregulator research programme. Readers should note this evidence base is almost entirely Russian preclinical and small-scale clinical research, published mainly in Russian-affiliated journals, and has not been replicated in Western randomised controlled trials. It should not be treated as equivalent in strength to Western RCT-based evidence.
- [Khavinson VK et al. 2010] — Tetrapeptide Ala-Glu-Asp-Pro (Cortagen) supports cortical neuron function and cognitive task recovery in aged and injured rat models. — Bulletin of Experimental Biology and Medicine — [Animal / Russian research programme]
- [Khavinson VK, Malinin VV] — Gerontological Aspects of Genome Peptide Regulation — Karger monograph — [Theoretical / mechanistic framework]
- [Ryzhak GA et al.] — Peptide bioregulators of the cerebral cortex and their role in age-related cognitive decline models — Advances in Gerontology — [Animal]
- [Khavinson VK et al.] — Short peptides and neurodegeneration markers in accelerated-ageing rodent strains — Neuroscience and Behavioral Physiology — [Animal / Russian research programme]
*This compliance check is automated and does not constitute legal advice. No Nonsense Fitness recommends independent legal review for all published content.*